Thrombophilia Panel 4

The Thrombophilia Panel 4 is a targeted genetic and biochemical screen for individuals with a personal or family history of abnormal blood clotting, recurrent thrombosis, or unexplained pregnancy loss. It examines key genetic variants and circulating proteins that influence platelet function, clot formation, vascular tone, and lipid handling, helping to clarify whether an inherited predisposition may be contributing to your thrombotic risk.

The panel uses polymerase chain reaction (PCR) based genotyping alongside standard biochemical assays to detect well-characterised polymorphisms and measure relevant protein markers. Results are interpreted in the context of your clinical history by your doctor.

Genetic Variants and Proteins Assessed

Platelet and Clotting Factors
- Glycoprotein IIIa (GPIIIa): a platelet membrane receptor variant that can influence platelet aggregation and thrombus formation.
- Fibrinogen-beta (Fibrinogen-β): a variant in the fibrinogen gene that may affect clot structure, density, and fibrinolytic resistance.

Lipid and Vascular Risk
- Apolipoprotein B (ApoB): a measure of atherogenic particle number, reflecting cardiovascular and thrombotic risk.
- Apolipoprotein E (ApoE): a genetic variant influencing lipid metabolism and vascular health.
- Angiotensin-converting enzyme (ACE): an enzyme involved in blood pressure regulation and endothelial function.

Endothelial Function
- Endothelial nitric oxide synthase (eNOS) [G894S, -786 T>C]: two common polymorphisms that can reduce nitric oxide availability, potentially impairing vasodilation and promoting a prothrombotic endothelial state.

Why it matters
Thrombophilia can remain silent until a triggering event such as surgery, immobility, pregnancy, or hormonal therapy precipitates a clot. Identifying inherited variants in GPIIIa, fibrinogen-beta, eNOS, and related markers allows you and your clinician to quantify risk, tailor preventive strategies, and make informed decisions about anticoagulation, lifestyle, and family screening. For those with a history of venous thromboembolism or recurrent miscarriage, this panel provides clarity that can guide safer clinical management.